Drugs / INM176
INM176
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05375539 | May 2023 → Feb 2025 | prostate cancer | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06600698 | May 2025 → May 2027 expected | prostate cancer | Milton S. Hershey Medical Center | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01245530 | Jun 2008 → Feb 2011 | Alzheimer disease | Whanin Pharmaceutical Company | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INM176 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06600698 ↗ |
| Known as | AGN-Cogni.Q | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05375539 ↗ |
| Known as | AGN-INM176 | “Evaluate Safety and Efficacy of Daily Oral Angelica Gigas Nakai (AGN)-INM176 in Prostate Patients With Rising Plasma PSA (Phase I/II Trial)” NCT06600698 ↗ |
| Known as | Cogni.QTM | “AGN-Cogni.Q, or Cogni.QTM, made with INM®176 proprietary ingredient” NCT05375539 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “herbal supplement INM176” NCT06600698 ↗ |
| Route | Oral | “600\~1200 mg orally every day” NCT01245530 ↗ |